Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenabasum in Cystic Fibrosis Phase 2 Trial
2017-003723-29Phase 2Completed
- Sponsor
- Corbus Pharmaceuticals Holdings, Inc.
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in cystic fibrosis (CF) comparing Lenabasum 20 mg BID with Placebo (2 arms). Primary endpoint: Rate of pulmonary exacerbations (primary definition). Started Feb 2018; status: completed.
02
Drugs
lenabasum
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2017-003723-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-003723-29.